Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic, relapsing-remitting autoimmune disease in which loss of immune tolerance to nuclear self-antigens drives autoantibody production and immune-complex-mediated inflammation across multiple organ systems.^[1] SLE is best understood as a spectrum: some patients have mild, clinically stable disease limited to skin and joints, while others develop severe, potentially life- or organ-threatening involvement of the kidneys, central nervous system, or blood. SLE also carries a substantially increased burden of comorbidity — cardiovascular disease, infection, and osteoporosis are major drivers of morbidity and mortality independent of lupus activity itself. There is no single diagnostic test; the diagnosis rests on a combination of characteristic clinical features, autoantibodies, and — when renal or other organ involvement is suspected — biopsy. Management layers onto every patient in the same order: hydroxychloroquine as background therapy regardless of severity, corticosteroids to control acute flares, and organ- and severity-matched immunosuppression (conventional agents, calcineurin inhibitors, or biologics) to induce and maintain remission while minimizing cumulative corticosteroid exposure.^[1]

SLE has a fluctuating course of relapses and remissions, and its multisystem presentation is why diagnosis can be delayed or missed — no single symptom or organ pattern is unique to lupus. The organ domains below are not mutually exclusive; most patients accumulate manifestations from more than one over time.

• Female sex, particularly during reproductive years — the age of peak disease onset.
• Family history of SLE or another autoimmune disease.
• Genetic factors, including complement deficiencies (e.g., C1q, C4) and certain HLA associations.
• Ultraviolet light exposure — can trigger both cutaneous and systemic flares.
• Cigarette smoking — worsens cutaneous damage accrual and reduces the effectiveness of antimalarial therapy.
• Certain medications capable of triggering drug-induced lupus (see Assessment & Diagnosis for the causative-drug list and how it differs from idiopathic SLE).
• Epstein-Barr virus and other environmental or infectious exposures implicated as disease triggers.
• Hormonal factors, including estrogen exposure.

Differentiating idiopathic SLE from drug-induced lupus

Distinguishing these matters because management is different — drug-induced lupus resolves after stopping the causative agent and does not need the immunosuppressive escalation used for idiopathic SLE.

A related but distinct phenomenon is drug-induced subacute cutaneous lupus, mediated by anti-Ro/SSA and anti-La/SSB antibodies rather than anti-histone antibodies — implicated drugs include calcium channel blockers, ACE inhibitors, hydrochlorothiazide, leflunomide, interferons, and terbinafine.

History

• Assess overall health status, quality of life, pregnancy history and current pregnancy plans, a complete medication review (screening for the causative drugs above), and vaccination record.

Physical examination

• Skin and oral mucosa for the cutaneous findings described in Recognize the Condition.
• Joints for synovitis in 2 or more joints with at least 30 minutes of morning stiffness.
• Imaging (chest x-ray, CT, ECG) when pleural effusion, pericardial effusion, or acute pericarditis is suspected.

Laboratory investigations

• CBC to identify cytopenias (anemia, leukopenia, thrombocytopenia).
• Creatinine, albumin, and urinalysis to screen for kidney involvement; quantify urine protein (spot protein-to-creatinine ratio) and pursue renal biopsy when indicated.
• Autoantibody panel and tissue biopsy as indicated to support the diagnosis (see table below).
• Anti-dsDNA — tracks with disease activity, kidney involvement, serositis, and hematologic manifestations, and is used to help monitor the clinical course over time.
• C3 and C4 complement levels — characteristically low during active disease.
• Anti-Ro/SSA and anti-La/SSB — particularly relevant when pregnancy is being considered or is present.
• Antiphospholipid antibodies — when there is an unexplained clot or pregnancy complication (see Special Populations for the antiphospholipid syndrome pathway).

Autoantibodies used in SLE evaluation

Classification criteria

No test or single feature is diagnostic of SLE; classification criteria give research cohorts a consistent case definition and are used clinically as a structured guide, not a diagnostic requirement — clinical judgment remains essential, since many individual features (arthritis, fatigue, pericarditis) are common in other conditions.^[2] The 2019 EULAR/ACR classification criteria require a positive ANA (titer of 1:80 or more on HEp-2 cells, or an equivalent positive test) at least once as an obligatory entry criterion. If met, points are summed across 7 clinical and 3 immunologic domains — only the single highest-weighted item within each domain counts toward the total — and a score of 10 or more, with at least 1 clinical criterion present, classifies the patient as having SLE.^[2]

This weighted, domain-capped scoring structure — where only the single highest-weighted criterion in each domain counts — is not a simple flat point-sum, so it is presented here as a teaching table rather than an interactive calculator; use the full published criteria or a validated tool for an actual classification decision.^[2]

• Achieve and maintain remission, or the lowest achievable disease activity, across every involved organ system.
• Prevent flares and prevent accrual of permanent organ damage.
• Minimize cumulative corticosteroid exposure — target prednisone under 5 mg/day (or off corticosteroids entirely) for maintenance, using corticosteroid-sparing agents to get there.
• Prevent, screen for, and treat the comorbidities disproportionately common in SLE — cardiovascular disease, infection, and osteoporosis.
• Support safe, planned pregnancy and preserve fertility when relevant to the patient.
• Improve long-term survival and quality of life.

• Patient education is foundational — most therapy decisions depend on the patient understanding why adherence (especially to hydroxychloroquine) matters even when feeling well.
• Sun protection: physical measures (protective clothing, a wide-brimmed hat) plus a broad-spectrum sunscreen SPF 30 or higher, applied daily — ultraviolet exposure triggers both cutaneous and systemic flares.
• Smoking cessation — reduces the already elevated cardiovascular risk in SLE and improves the effectiveness of antimalarial therapy.
• Heart-healthy diet and regular exercise as tolerated.
• Confirm immunizations are up to date, using inactivated vaccines, before starting or escalating immunosuppression; avoid live vaccines once a patient is significantly immunosuppressed.
• Adequate calcium and vitamin D intake plus weight-bearing exercise to offset the osteoporosis risk from sun avoidance and corticosteroid exposure.
• Discuss contraception and family planning at every visit with a reproductive-age patient (see Special Populations).
• Cervical cancer screening per standard guidance in sexually active patients under 69 years of age.

Medications requiring a switch before conception

• Methotrexate — stop at least 3 months before attempting conception; switch to hydroxychloroquine and/or azathioprine.
• Mycophenolate mofetil/sodium — stop at least 6 weeks before attempting conception; switch to azathioprine, observing disease activity for at least 6 months before conception where possible.
• Cyclophosphamide — teratogenic; also carries a real fertility-preservation concern independent of the pregnancy-timing issue (see below).
• Leflunomide — teratogenic; if pregnancy is desired, either wait 2 years after stopping, or complete a washout (cholestyramine 8 g PO three times daily, or activated charcoal 50 g PO 4 times daily, for 11 days, not necessarily consecutive) followed by 2 plasma level checks at least 14 days apart confirming a concentration under 0.02 mg/L before conceiving. Cholestyramine and activated charcoal both reduce combined oral contraceptive absorption — use a non-hormonal contraceptive method during the washout.

Fertility preservation

Cyclophosphamide can cause permanent infertility depending on cumulative dose and patient age; discuss fertility preservation (GnRH agonist co-therapy, oocyte or embryo cryopreservation) before starting cyclophosphamide in a patient who may want a future pregnancy.

Antiphospholipid syndrome overlap

Antiphospholipid antibodies (anticardiolipin, lupus anticoagulant, anti-beta-2-glycoprotein I) occur in a substantial minority of SLE patients and define antiphospholipid syndrome (APS) when accompanied by a qualifying thrombotic or obstetric event, confirmed on 2 occasions at least 12 weeks apart.^[5] Management is risk- and event-stratified, not uniform:

• Antiphospholipid antibody-positive, no prior thrombotic or obstetric event: primary thromboprophylaxis with low-dose ASA, particularly with a high-risk antibody profile (triple positivity, lupus anticoagulant, or persistently high titers); continue hydroxychloroquine, which itself carries antithrombotic benefit.^[5]
• First venous thrombotic event: indefinite vitamin K antagonist (warfarin), target INR 2-3. Direct oral anticoagulants are not recommended, particularly with triple-positive or arterial/recurrent disease, given evidence of a higher recurrence rate compared with warfarin.^[5]
• Arterial thrombotic event: indefinite vitamin K antagonist, target INR 2-3 (some specialists use a higher target or add low-dose ASA in a high-risk profile) — specialist-directed.^[5]
• Obstetric APS (recurrent early pregnancy loss, a loss at or after 10 weeks, or preterm delivery for placental insufficiency): low-dose ASA plus prophylactic-dose heparin (unfractionated or low-molecular-weight) throughout pregnancy — the combination improves live birth rate and reduces preeclampsia risk compared with ASA alone.^[5]
• Catastrophic APS (see Red Flags & Refer) — a medical emergency requiring combination anticoagulation, high-dose corticosteroid, and specialist-directed adjunctive therapy (e.g., plasma exchange or IVIG).

Pediatric and adolescent-onset SLE

Childhood-onset SLE tends to be more severe, with a higher rate of lupus nephritis, and needs pediatric rheumatology involvement; hydroxychloroquine dosing follows the same actual-body-weight ceiling (5 mg/kg/day or less).

Renal impairment

Dose-adjust azathioprine, mycophenolate, and methotrexate for reduced renal function; avoid or minimize NSAID use given additional nephrotoxicity risk on top of lupus nephritis. Voclosporin has a specific eGFR-triggered dose-reduction protocol (see Drug Tables).

Older adults

Increased vigilance for infection and malignancy is needed with chronic immunosuppression, and corticosteroid-related fracture risk is higher — reinforce bone-health measures (see Monitoring & Follow-Up).

Disease activity and cumulative organ damage are assessed by a specialist using structured composite instruments (e.g., SLEDAI for activity, the SLICC/ACR Damage Index for damage) — these are specialist-administered composite tools requiring detailed exam and laboratory findings, not a simple point-sum a pharmacist calculates at point of care, so no self-service calculator is provided here; pharmacists should instead track the individual lab trends and clinical findings below and flag concerning changes to the treating specialist.

• Follow-up interval: every 1-3 months for active disease; every 6-12 months for mild or inactive disease.^[1]
• At each visit on immunosuppression: CBC, creatinine, urinalysis (with a urine protein-to-creatinine ratio when indicated), and agent-specific labs (see Drug Tables for the exact monitoring schedule by drug).
• Trend anti-dsDNA and C3/C4 complement over time — rising anti-dsDNA with falling complement can herald a flare, particularly renal.
• Cardiovascular risk factor screening and management at every visit — blood pressure, lipids, glucose, weight, and smoking status — given the markedly elevated cardiovascular risk in SLE.
• Bone health: baseline and periodic bone density (DXA) in patients on chronic corticosteroids; ensure adequate calcium (1200 mg/day elemental, from all sources) and vitamin D (at least 1000 units/day); start a bisphosphonate for corticosteroid-induced osteoporosis prevention in a patient taking prednisone 7.5 mg/day or more for 6 months or longer who also has a hip/spine Z-score under -3 or more than 10% per year bone loss, or in anyone taking 30 mg/day or more with a cumulative dose over 5 g in 1 year.
• Ophthalmologic screening for hydroxychloroquine retinopathy: a baseline exam at or soon after starting, then annual screening (OCT plus wide-field autofluorescence as the primary tests, with visual field or ERG as confirmatory) starting after 5 years of use in an average-risk patient, or from the outset in a high-risk patient (dose over 5 mg/kg/day actual body weight, treatment beyond 5 years, renal impairment, concurrent tamoxifen, older age at initiation, or pre-existing retinal disease).^[6]
• Screen for osteonecrosis symptoms (joint pain out of proportion to known disease activity, especially hip or knee) in a patient with substantial cumulative glucocorticoid exposure; image if suspected.
• Review immunization status at least annually and before any escalation of immunosuppression.
• Cervical cancer screening per standard guidance in sexually active patients under 69 years of age.

1. Confirm adherence to hydroxychloroquine and the current regimen before escalating therapy — nonadherence is a common cause of apparent treatment failure, and abruptly stopping hydroxychloroquine can itself trigger a flare.
2. Distinguish a true flare from infection or another mimicking process before intensifying immunosuppression — treating an infection as a flare can be dangerous, and vice versa.
3. Confirm the corticosteroid dose and taper pace matched the severity and organ involved — under-dosing organ-threatening disease is a common, preventable cause of apparent treatment failure.
4. If flaring on hydroxychloroquine plus corticosteroid alone, or unable to taper prednisone toward the maintenance target, add a corticosteroid-sparing immunosuppressant matched to the dominant manifestation.
5. If flaring despite an adequate trial of a first corticosteroid-sparing agent, or in organ-threatening disease not responding to standard induction, escalate to a biologic (belimumab or anifrolumab, matched to indication) or refer for cyclophosphamide or rituximab under specialist direction.
6. For lupus nephritis specifically not achieving response at 3-6 months of induction therapy, refer promptly for repeat renal biopsy and specialist reassessment rather than prolonging an ineffective regimen — the histologic class can change over time, and the treatment plan needs to match the current biopsy findings.^[3]

• Stopping hydroxychloroquine in a patient with stable disease — withdrawal is a well-documented flare trigger; continue indefinitely unless there is a genuine contraindication.
• Exceeding the hydroxychloroquine 5 mg/kg actual-body-weight ceiling, or missing scheduled ophthalmologic screening.
• Treating lupus nephritis as "quiet" because the patient feels well — renal disease is frequently clinically silent and must be actively screened for with labs, not inferred from symptoms.
• Under-treating organ-threatening disease with a low-dose corticosteroid alone instead of the indicated high-dose corticosteroid plus induction immunosuppressant.
• Giving a live vaccine to a patient on significant immunosuppression.
• Missing NSAID-induced aseptic meningitis as a cause of headache or meningismus in an SLE patient — a real, drug-specific mimicker of CNS lupus.
• Attributing every new symptom automatically to "a flare" without excluding infection or an unrelated cause first, especially in a febrile immunosuppressed patient.
• Using sulfamethoxazole/trimethoprim without caution — it can itself trigger a photosensitive rash or flare, though it remains indicated as Pneumocystis jirovecii pneumonia prophylaxis during potent immunosuppression.
• Continuing methotrexate or mycophenolate too long in a patient planning conception, instead of switching to a pregnancy-compatible agent with adequate lead time.
• Choosing a direct oral anticoagulant instead of warfarin for a patient with thrombotic antiphospholipid syndrome.
• Missing a bone-health plan (calcium, vitamin D, bisphosphonate when indicated) in a patient on long-term moderate-to-high-dose corticosteroids.

How to use this table: Doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.

Antimalarials

The only antimalarial used in SLE — chloroquine carries a higher retinal toxicity risk and is no longer marketed in Canada.

Corticosteroids

Route and dose scale with disease severity; combine with a corticosteroid-sparing agent whenever more than a brief course is needed.

Conventional immunosuppressants

Calcineurin inhibitors

Used for refractory or membranous (Class V) lupus nephritis, or as an add-on to mycophenolate per current combination-therapy guidance; monitor drug levels, blood pressure, renal function, and metabolic parameters closely with all agents in this class.

Biologics

Refractory cutaneous disease

Reserved for cutaneous lupus refractory to hydroxychloroquine and standard immunosuppression, given significant adverse-effect burden.

NSAIDs and antiplatelet therapy

High-dose NSAIDs have been associated with aseptic meningitis in SLE patients specifically, and all NSAIDs carry cardiovascular risk — use the lowest effective dose for the shortest duration.

Antiphospholipid syndrome anticoagulation

See Special Populations for the full risk- and event-stratified approach.

Bone health

For prevention and treatment of corticosteroid-induced osteoporosis — see Monitoring & Follow-Up for the specific dose/duration thresholds that trigger bisphosphonate therapy.

Infection prophylaxis and vaccination

Evaluate immunization status before starting immunosuppression; use inactivated vaccines and avoid live vaccines (e.g., the live-attenuated zoster or MMR vaccines) once a patient is significantly immunosuppressed.

Topical/cutaneous therapy

For isolated cutaneous lupus not requiring systemic escalation.